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Background
The need for opioid analgesics with reduced undesirable
side-effects has initiated a vast amount of scientific efforts,
which have led to a number of new opioid ligands and sig-
nificant expansion of knowledge in opioid pharmacology.
The development of morphinans anellated with hetero-
cycles gave rise to several potential therapeutic agents and
useful pharmacological tools.
Methods
The chemistry involved the design and synthesis of two
sets of oxazolomorphinans having the new heteroring
anellated to the A-ring of the morphinan backbone.
Binding affinities of the newly synthesized compounds at
opioid receptors were determined by in vitro competition
binding assays using rat brain (μ, δ) and guinea pig brain
() membranes and employing [3H]DAMGO (μ), [3H]
[Ile5,6]deltorphin II (δ) and [3H]U-69,593 () as specific
opioid radioligands. The in vitro pharmacological activ-
ities were established using [35S]GTPgS functional assays
in membranes from Chinese hamster ovary (CHO) cells
expressing human opioid receptors.
Results
Binding studies on the newly synthesized N-methyl
and N-allyl derivatives to opioid receptors revealed
remarkable results for three compounds: the amino-
substituted N-methyloxazolomorphinan showed high
affinity and selectivity to the μ opioid receptor, while
two N-allyloxazolomorphinans were found to interact
with high affinity with μ and  sites and moderate
binding towards δ receptors. In ligand-stimulated [35S]
GTPgS binding studies, the N-methyl congener acted
as a potent and full agonist at the μ receptor. The two
N-allyl derivatives showed antagonistic effects at μ and
 receptors.
Conclusions
The design and synthesis of novel oxazolomorphinans
led to an interesting alteration in opioid activity by
influencing the biological and pharmacological profile of
these compounds interacting with μ, δ and  opioid
receptors.
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